IL129292A0 - Fusogenic liposome composition and method - Google Patents

Fusogenic liposome composition and method

Info

Publication number
IL129292A0
IL129292A0 IL12929297A IL12929297A IL129292A0 IL 129292 A0 IL129292 A0 IL 129292A0 IL 12929297 A IL12929297 A IL 12929297A IL 12929297 A IL12929297 A IL 12929297A IL 129292 A0 IL129292 A0 IL 129292A0
Authority
IL
Israel
Prior art keywords
liposome
composition
target cells
hydrophobic polymers
liposome composition
Prior art date
Application number
IL12929297A
Other languages
English (en)
Original Assignee
Sequus Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequus Pharm Inc filed Critical Sequus Pharm Inc
Publication of IL129292A0 publication Critical patent/IL129292A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IL12929297A 1996-10-11 1997-10-10 Fusogenic liposome composition and method IL129292A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2826996P 1996-10-11 1996-10-11
PCT/US1997/018838 WO1998016202A2 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method

Publications (1)

Publication Number Publication Date
IL129292A0 true IL129292A0 (en) 2000-02-17

Family

ID=21842486

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12929297A IL129292A0 (en) 1996-10-11 1997-10-10 Fusogenic liposome composition and method

Country Status (15)

Country Link
US (1) US5891468A (de)
EP (1) EP0932391B1 (de)
JP (1) JP2001504093A (de)
AT (1) ATE232086T1 (de)
AU (1) AU715063B2 (de)
BR (1) BR9712230A (de)
CA (1) CA2267904C (de)
DE (1) DE69718924T2 (de)
DK (1) DK0932391T3 (de)
ES (1) ES2191833T3 (de)
HK (1) HK1047550A1 (de)
IL (1) IL129292A0 (de)
PT (1) PT932391E (de)
TW (1) TW520297B (de)
WO (1) WO1998016202A2 (de)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US6008202A (en) * 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5795587A (en) * 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
US20070036722A1 (en) * 1996-10-28 2007-02-15 Pal Rongved Separation processes
US6210707B1 (en) * 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
EP0956001B1 (de) * 1996-11-12 2012-09-12 The Regents of The University of California Herstellung stabiler formulierungen von lipid-nukleinsäure komplexen zur effizienten in-vivo verabreichung
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
US7087770B2 (en) 1998-05-16 2006-08-08 Mirus Bio Corporation Compound containing a labile disulfide bond
US6936729B2 (en) * 1998-05-16 2005-08-30 Mirus Bio Corporation Compound containing a labile disulfide bond
US6355268B1 (en) 1998-09-16 2002-03-12 Alza Corporation Liposome-entrapped topoisomerase inhibitors
JP2002532407A (ja) * 1998-12-18 2002-10-02 アルザ・コーポレーション 多薬物耐性細胞に対する化合物の投与方法
US6379698B1 (en) * 1999-04-06 2002-04-30 Isis Pharmaceuticals, Inc. Fusogenic lipids and vesicles
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
JP5117648B2 (ja) * 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア カチオン性ｐｅｇ脂質および使用方法。
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US7238368B2 (en) * 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
IL146047A0 (en) * 1999-04-23 2002-07-25 Alza Corp Releasable linkage and compositions containing same
US6342244B1 (en) * 1999-04-23 2002-01-29 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) * 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
EP1180242A1 (de) * 1999-05-27 2002-02-20 Zeptosens AG Polymer-enthaltendes vesikel und darauf basierte sensor-nachweisverfahren
KR20070086708A (ko) 1999-07-14 2007-08-27 알자 코포레이션 중성 지질중합체 및 그를 함유하는 리포솜 조성물
WO2001026625A2 (en) * 1999-10-08 2001-04-19 Alza Corp Neutral-cationic lipid for nucleic acid and drug delivery
US20040197390A1 (en) * 2001-05-29 2004-10-07 Shi-Kun Huang Neutral-cationic lipid for systemic delivery of factor VIII gene
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6916488B1 (en) * 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
AU1776801A (en) * 1999-11-24 2001-06-04 Liposome Company, Inc., The Modular targeted liposomal delivery system
CA2393595A1 (en) * 1999-12-10 2001-06-14 Gigi Chiu Lipid carrier compositions with protected surface reactive functions
MXPA02007320A (es) * 2000-01-28 2004-07-30 Alza Corp Liposomas conteniendo un compuesto atrapado en solucion supersaturada.
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
AU2001254548B2 (en) * 2000-04-20 2006-09-28 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
US10293056B1 (en) * 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
IL153218A0 (en) 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
US6998115B2 (en) 2000-10-10 2006-02-14 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
EP1341497A4 (de) * 2000-11-02 2005-10-19 Smithkline Beecham Corp Rezeptor-antagonisten-lipid-konjugate und diese enthaltende abgabeträger
US6613280B2 (en) 2001-03-20 2003-09-02 Therox, Inc. Disposable cartridge for producing gas-enriched fluids
WO2002076394A2 (en) * 2001-03-22 2002-10-03 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
NZ528523A (en) * 2001-03-26 2006-03-31 Alza Corp Liposome composition for improved intracellular delivery of a therapeutic agent
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
EP3231445A1 (de) * 2001-05-18 2017-10-18 Sirna Therapeutics, Inc. Konjugate und zusammensetzungen zur zellulären verabreichung
US20050158735A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
AU2002329176A1 (en) 2001-05-25 2002-12-23 The Trustees Of The University Of Pennsylvania Targeted particles and methods of using the same
US6939564B2 (en) * 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
EP2325193A3 (de) 2001-11-02 2012-05-02 Insert Therapeutics, Inc. Verfahren und Zusammensetzungen zur therapeutischen Verwendung von RNA-Interferenz
GB0129121D0 (en) * 2001-12-05 2002-01-23 Ic Vec Ltd Compound
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1485076A1 (de) * 2002-02-27 2004-12-15 The Ohio State University Research Foundation Therapeutische verfahren für akute myeloische leukämie
US7018655B2 (en) * 2002-03-18 2006-03-28 Labopharm, Inc. Amphiphilic diblock, triblock and star-block copolymers and their pharmaceutical compositions
WO2003083443A2 (en) * 2002-03-29 2003-10-09 University Of Florida Lipid mediated screening of drug candidates for identification of active compounds
US20060094673A1 (en) * 2002-04-23 2006-05-04 Benjamin Chu Polymer surfactants for gene therapy applications
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
US20040093198A1 (en) * 2002-11-08 2004-05-13 Carbon Design Systems Hardware simulation with access restrictions
EP1581582B2 (de) 2003-01-06 2017-06-07 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
EP1591450A4 (de) * 2003-01-10 2006-05-17 Yamanouchi Pharma Co Ltd Konjugat für retention im blut und krebsgewebespezifische wirkstofffreisetzung
MXPA05009137A (es) * 2003-02-28 2005-10-20 Johnson & Johnson Composicion de liposoma para reducir la activacion del complemento inducida por liposoma.
WO2004089339A2 (en) 2003-03-31 2004-10-21 Alza Corporation Lipid particles having asymmetric lipid coating and method of preparing same
US20050025822A1 (en) * 2003-05-30 2005-02-03 Wong Frances M.P. Method of pulmonary administration of an agent
US11324698B2 (en) * 2003-08-28 2022-05-10 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
US8846079B1 (en) * 2004-12-01 2014-09-30 Vgsk Technologies, Inc. Sterically stabilized carrier for aerosol therapeutics, compositions and methods for treating the respiratory tract of a mammal
AU2004267875B2 (en) * 2003-08-29 2010-09-02 Newcastle Innovation Limited Stimulant sensitive flocculation and consolidation
US7943179B2 (en) 2003-09-23 2011-05-17 Massachusetts Institute Of Technology pH triggerable polymeric particles
AU2004283758A1 (en) * 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
KR20060103957A (ko) * 2004-01-15 2006-10-04 알자 코포레이션 치료제 전달용의 리포솜 조성물
US8168222B2 (en) 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
US8017151B2 (en) * 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
AU2005295072A1 (en) * 2004-10-08 2006-04-20 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
WO2006088245A1 (ja) * 2005-02-18 2006-08-24 The University Of Tokushima ポリオキシアルキレン鎖含有脂質誘導体及び該誘導体を含有する脂質膜構造体
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
WO2006127360A2 (en) * 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of interferon to a mammal
EP1891141B1 (de) 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblockcopolymere zur zytoplasmatischen zuführung von arzneistoffen auf genbasis
EP3067046B1 (de) 2005-12-08 2020-03-25 Insmed Incorporated Antiinfektive zusammensetzungen auf lipidbasis zur behandlung von lungeninfekten
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US8808681B2 (en) 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
US20080031883A1 (en) * 2006-07-13 2008-02-07 Torchilin Vladimir P Condition-dependent, multiple target delivery system
WO2008008523A1 (en) * 2006-07-14 2008-01-17 Regents Of The University Of Minnesota COMPOUNDS THAT BIND α5β1 INTEGRIN AND METHODS OF USE
CA2658768C (en) 2006-07-21 2016-05-17 Massachusetts Institute Of Technology End-modified poly(beta-amino esters) and uses thereof
US20080213349A1 (en) * 2006-09-11 2008-09-04 Deepak Ramesh Thakker Liposome Complexes Containing Pharmaceutical Agents and Methods
EP2081548A2 (de) * 2006-09-22 2009-07-29 Labopharm Inc. Zusammensetzungen und verfahren für die ph-gezielte arzneiabgabe
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
WO2009091531A2 (en) * 2008-01-16 2009-07-23 The General Hospital Corporation Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
WO2009154688A1 (en) * 2008-05-28 2009-12-23 President And Fellows Of Harvard College A pre-fabricated electron microscopy grid for monolayer purification and methods and kits therefor
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
KR101647334B1 (ko) 2008-07-10 2016-08-10 세리나 쎄라퓨틱스, 인코포레이티드 불활성 말단기를 가진 폴리옥사졸린, 보호된 개시기로부터 제조된 폴리옥사졸린 및 그와 관련된 화합물
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9271929B2 (en) 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
AU2009329917B2 (en) 2008-12-23 2016-03-31 Gilead Pharmasset Llc Nucleoside analogs
CN102695513A (zh) 2008-12-23 2012-09-26 吉利德制药有限责任公司 核苷氨基磷酸酯
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
EP2230515B1 (de) * 2009-03-16 2014-12-17 Agilent Technologies, Inc. Passivierung von Oberflächen nach Ligandenkupplung
CA3042927C (en) 2009-05-05 2022-05-17 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2011017297A2 (en) * 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
HUE031793T2 (en) 2009-08-31 2017-07-28 Nanocarrier Co Ltd Particle composition and pharmaceutical composition containing such
DK3338765T3 (en) 2009-12-01 2019-03-04 Translate Bio Inc STEROID DERIVATIVE FOR THE SUPPLY OF MRNA IN HUMANGENETIC DISEASES
JP4829351B2 (ja) 2010-02-05 2011-12-07 ナノキャリア株式会社 易崩壊型ポリマーミセル組成物
SMT201700412T1 (it) 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
JP5872539B2 (ja) 2010-03-31 2016-03-01 ギリアド ファーマセット エルエルシー プリンヌクレオシドホスホルアミダート
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
KR20130060223A (ko) 2010-05-04 2013-06-07 메리맥 파마슈티컬즈, 인크. 상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
CN107261110A (zh) 2010-06-19 2017-10-20 健康科学西部大学 Peg化脂质体包封的糖肽抗生素的新制剂
EP2609135A4 (de) 2010-08-26 2015-05-20 Massachusetts Inst Technology Poly(beta-amino-alkohole), ihre herstellung und verwendungen davon
EP3327125B1 (de) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
JP2014519493A (ja) * 2011-05-12 2014-08-14 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド ポリマー共役脂質を含むリポソームおよび関連用途
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
JP6184945B2 (ja) 2011-06-08 2017-08-23 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ｍＲＮＡ送達のための脂質ナノ粒子組成物および方法
US8883989B2 (en) 2011-10-18 2014-11-11 Regents Of The University Of Minnesota Fractalkine binding polynucleotides and methods of use
EA032088B1 (ru) 2011-10-27 2019-04-30 Массачусетс Инститьют Оф Текнолоджи Аминокислотные производные, функционализованные на n-конце, способные образовывать микросферы, инкапсулирующие лекарственное средство
EP3536787A1 (de) 2012-06-08 2019-09-11 Translate Bio, Inc. Nukleaseresistente polynukleotide und verwendungen davon
EP2874605A1 (de) 2012-07-18 2015-05-27 Onyx Therapeutics, Inc. Liposomale zusammensetzungen von proteasomhemmern auf epoxyketonbasis
CN102920658B (zh) * 2012-11-02 2015-01-21 艾韦特(溧阳)医药科技有限公司 与glp-1类似物和聚乙二醇结合的脂质体及其制备方法
US10124066B2 (en) 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
BR112015022819A8 (pt) * 2013-03-13 2019-11-26 Mallinckrodt Llc método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal
IL305374A (en) 2013-03-14 2023-10-01 Ethris Gmbh Cftr mrna compositions and related methods and uses
JP6586075B2 (ja) 2013-03-14 2019-10-02 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
BR112016009014B1 (pt) 2013-10-22 2024-02-06 Translate Bio, Inc USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE
AU2014340155B2 (en) 2013-10-22 2018-11-01 Massachusetts Institute Of Technology Lipid formulations for delivery of messenger RNA
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
US9770489B2 (en) 2014-01-31 2017-09-26 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery
WO2015148971A2 (en) 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
RU2736495C2 (ru) 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
MX373952B (es) 2014-04-25 2020-07-13 Shire Human Genetic Therapies Métodos de purificación de arn mensajero.
CN106535877A (zh) 2014-05-15 2017-03-22 英斯梅德股份有限公司 用于治疗肺部非结核性分枝杆菌感染的方法
MA48050A (fr) 2014-05-30 2020-02-12 Translate Bio Inc Lipides biodégradables pour l'administration d'acides nucléiques
EA033966B1 (ru) 2014-06-24 2019-12-13 Транслейт Био, Инк. Стереохимически обогащенные композиции для доставки нуклеиновых кислот
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
CN104546722B (zh) * 2015-02-10 2017-05-24 中国医学科学院医药生物技术研究所 米铂脂质体和制法
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN107848988B (zh) 2015-06-19 2021-10-22 麻省理工学院 烯基取代的2,5-哌嗪二酮和其在组合物中用于向个体或细胞递送药剂的用途
JP6894423B2 (ja) 2015-07-09 2021-06-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 融合性リポソーム被覆多孔質ケイ素ナノ粒子
CN108289845A (zh) 2015-09-14 2018-07-17 维吉思康科技公司 皮下、舌下和口服治疗用空间稳定载体、用于治疗哺乳动物的组合物和方法
US10583083B1 (en) 2016-08-10 2020-03-10 Verily Life Sciences Llc ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages
US10517823B1 (en) * 2016-08-10 2019-12-31 Verily Life Sciences Llc ROS—responsive liposomes for specific targeting
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion
EP3585417B1 (de) 2017-02-27 2023-02-22 Translate Bio, Inc. Methode der herstellung von codon-optimierter cftr-mrna
CA3056797A1 (en) 2017-03-16 2018-09-20 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
EP3612161A4 (de) * 2017-04-19 2021-02-17 APA- Advanced Technologies Ltd. Fusogene liposomen, zusammensetzungen, kits und verwendung davon zur behandlung von krebs
EP3624824B1 (de) 2017-05-16 2024-07-10 Translate Bio, Inc. Codonoptimierter mrna, die cftr codiert, zur verwendung in der behandlung von zystischer fibrose
US11464860B2 (en) 2017-10-27 2022-10-11 Massachusetts Institute Of Technology Poly (beta-amino esters) and uses thereof
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
JP2022505714A (ja) * 2018-10-24 2022-01-14 エイピーエイ－ アドバンスト・テクノロジーズ・リミテッド 腫瘍細胞の選択的イメージングのための融合性リポソーム
WO2020086965A1 (en) 2018-10-26 2020-04-30 Massachusetts Institute Of Technology Polymer-lipids and compositions
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
EP4305088A1 (de) 2021-03-09 2024-01-17 Massachusetts Institute of Technology Verzweigte poly(aminoester) zur verabreichung von nukleinsäuren
AU2022270670A1 (en) 2021-05-05 2023-11-30 Nejat Duzgunes Liposome-encapsulated corticosteriods inhibit sars-cov-2 replication and reduces lung inflammation
JPWO2023210671A1 (de) * 2022-04-26 2023-11-02

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5136095A (en) * 1987-05-19 1992-08-04 Syntex (U.S.A.) Inc. Reversible agglutination mediators
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
JPH07173079A (ja) * 1992-12-22 1995-07-11 Nippon Oil & Fats Co Ltd 両親媒性ポリエチレングリコール誘導体および用途
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes

Also Published As

Publication number Publication date
WO1998016202A2 (en) 1998-04-23
DK0932391T3 (da) 2003-05-26
TW520297B (en) 2003-02-11
ES2191833T3 (es) 2003-09-16
AU715063B2 (en) 2000-01-13
EP0932391B1 (de) 2003-02-05
HK1047550A1 (en) 2003-02-28
EP0932391A2 (de) 1999-08-04
US5891468A (en) 1999-04-06
BR9712230A (pt) 2000-01-25
WO1998016202A3 (en) 1998-07-16
DE69718924T2 (de) 2003-12-04
CA2267904C (en) 2005-08-02
JP2001504093A (ja) 2001-03-27
CA2267904A1 (en) 1998-04-23
PT932391E (pt) 2003-06-30
AU4987897A (en) 1998-05-11
ATE232086T1 (de) 2003-02-15
DE69718924D1 (de) 2003-03-13

Similar Documents

Publication Publication Date Title
IL129292A0 (en) Fusogenic liposome composition and method
AU1742597A (en) A hydrophilic, graphite fuel cell electrode for use with an ionomer membrane and method of making a fuel cell
MY122195A (en) New controlled release bead, a method of producing the same and multiple unit formulation comprising it
AU3985697A (en) Liposomes containing a cisplatin compound
IL142573A0 (en) Liposome-entrapped topoisomerase inhibitors
EP0806397A4 (de) Lithium-nickel-verbundoxid, verfahren zu seiner herstellung und positives aktives material für sekundäre batterie
AU590565B2 (en) Controlled release delivery system for macromolecules
CA2207801A1 (en) Nonaqueous electrolyte battery
WO2001057940A3 (en) Freestanding microporous separator including a gel-forming polymer
GB9708365D0 (en) Proton conducting membranes
AU6266398A (en) Method of preparing electrochemical cells
MXPA02004574A (es) Formulacion farmaceutica que contiene tolterodina y su uso.
AU2947597A (en) Electrode material for rechargeable batteries and process for the preparation thereof
AU2124495A (en) Bipolar battery cells, batteries, and methods
AU4451597A (en) An electrolyte system, a method for the preparation thereof, the use thereof and a battery containing the electrolyte system
NZ297537A (en) method for changing the cell characteristics of the female reproductive tract
AU7672296A (en) Method of preparing electrochemical cells
EP0845824B8 (de) Lithiumsekundärbatterie und aktives Kathodenmaterial zur Verwendung in einer Lithiumsekundärbatterie
AU4302100A (en) Ketoprofen microgranules, method for preparing same and pharmaceutical compositions
GB9724826D0 (en) An active material for a cathode of lithium ion battery and a method for preparing the same
IE853107L (en) Theophylline sustained release formulation
AU6354196A (en) A wound electrochemical cell, a method for the manufacture thereof, and the use of such electrochemical cells
AU7277598A (en) Energy delivery of catheter and method for the use thereof
EP1214935A3 (de) Fusogene Liposomenzusammensetzung und Verfahren
AU1226699A (en) Composite suitable for use in electrochemical cells

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees